Hydroxychloroquinesulfaat Doc

Hydroxychloroquine sulfate, the active ingredient in Hydroxychloroquinesulfaat Doc, is an antimalarial presented as an oral tablet for oral use. It treats malaria and is used as a disease‑modifying antirheumatic drug in rheumatoid arthritis and systemic lupus erythematosus.

GNH USA supplies Hydroxychloroquinesulfaat Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Hydroxychloroquine sulfate is employed in several infectious and autoimmune disease pathways. - Malaria: Reduces parasite replication and clears blood‑stage infection. - Rheumatoid arthritis: Decreases joint inflammation and slows disease progression. - Systemic lupus erythematosus: Controls disease activity and reduces flare frequency.

Hydroxychloroquine sulfate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Retinopathy: progressive vision loss requiring ophthalmologic monitoring. - Cardiac toxicity: arrhythmias or cardiomyopathy. - Severe hypoglycemia: especially in diabetic patients.

When prescribing hydroxychloroquine sulfate, clinicians should observe several precautionary measures to ensure patient safety. - Baseline eye exam: perform ophthalmologic assessment before therapy and annually thereafter. - Cardiac monitoring: evaluate ECG and cardiac function in patients with pre‑existing heart disease. - Renal impairment: adjust use in severe renal dysfunction. - Concomitant QT‑prolonging drugs: avoid or monitor for additive effects. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Hydroxychloroquine sulfate interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Azithromycin: combined QT prolongation risk. - Amiodarone: additive cardiac conduction effects. - Digoxin: increased serum levels.

Moderate Interactions (Monitor Closely): - Antacids (aluminum, magnesium): may reduce absorption. - CYP2D6 inhibitors (e.g., fluoxetine): may increase plasma concentrations. - Warfarin: potential alteration of anticoagulant effect.